Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...
Exelixis, Merck Sign Zanzalintinib Development Collaboration
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
GlobalData on MSN3d
Exelixis and MSD to trial cancer therapies together in clinical collaboration
"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...
Pharmabiz3d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
Investing4d
Exelixis shares poised for growth with zanzalintinib’s expanded trials, Citi maintains bullish outlook
The endorsement follows Exelixis' announcement of a new clinical development collaboration with Merck, focusing on Exelixis' next-generation tyrosine kinase inhibitor (TKI), zanzalintinib.
Nasdaq4d
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
The companies will also evaluate zanzalintinib with WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for ...